MX2020003046A - Anticuerpos anti-hla-a2 y metodos para utilizar los mismos. - Google Patents

Anticuerpos anti-hla-a2 y metodos para utilizar los mismos.

Info

Publication number
MX2020003046A
MX2020003046A MX2020003046A MX2020003046A MX2020003046A MX 2020003046 A MX2020003046 A MX 2020003046A MX 2020003046 A MX2020003046 A MX 2020003046A MX 2020003046 A MX2020003046 A MX 2020003046A MX 2020003046 A MX2020003046 A MX 2020003046A
Authority
MX
Mexico
Prior art keywords
hla
antibodies
methods
car
humanized anti
Prior art date
Application number
MX2020003046A
Other languages
English (en)
Inventor
Jan Peter Bergqvist
Megan Levings
Paul Orban
Nicholas Dawson
Caroline Lamarche
Original Assignee
Univ British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ British Columbia filed Critical Univ British Columbia
Publication of MX2020003046A publication Critical patent/MX2020003046A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46434—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464403—Receptors for growth factors
    • A61K39/464406—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Abstract

Se proporcionan anticuerpos anti-HLA-A2 humanizados. En ciertos aspectos, los anticuerpos anti-HLA-A2 humanizados son capaces de constituir un dominio de unión a antígeno de un receptor de antígeno quimérico (CAR), en donde el CAR es capaz de expresarse en una célula humana de tal manera que el CAR se une específicamente a HLA-A2. También se proporcionan CARs que incluyen los anticuerpos humanizados anti-HLA-A2. También se proporcionan células modificadas que incluyen los anticuerpos y CARs, así como métodos para utilizar dichas células modificadas.
MX2020003046A 2017-09-19 2018-09-19 Anticuerpos anti-hla-a2 y metodos para utilizar los mismos. MX2020003046A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762560574P 2017-09-19 2017-09-19
US201862692386P 2018-06-29 2018-06-29
PCT/CA2018/051167 WO2019056099A1 (en) 2017-09-19 2018-09-19 ANTI-HLA-A2 ANTIBODIES AND METHODS OF USE

Publications (1)

Publication Number Publication Date
MX2020003046A true MX2020003046A (es) 2020-10-12

Family

ID=65809516

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020003046A MX2020003046A (es) 2017-09-19 2018-09-19 Anticuerpos anti-hla-a2 y metodos para utilizar los mismos.

Country Status (12)

Country Link
US (1) US20200283529A1 (es)
EP (1) EP3684821A4 (es)
JP (2) JP7281774B2 (es)
KR (1) KR20200067845A (es)
CN (1) CN111448215B (es)
AU (1) AU2018338418A1 (es)
BR (1) BR112020005361A2 (es)
CA (1) CA3076261A1 (es)
IL (1) IL273402A (es)
MX (1) MX2020003046A (es)
SG (1) SG11202002520UA (es)
WO (1) WO2019056099A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3058425A1 (en) 2017-03-28 2018-10-04 The Trustees Of The University Of Pennsylvania Methods to protect transplanted tissue from rejection
BR112020005519A2 (pt) * 2017-09-20 2020-10-27 The University Of British Columbia novos anticorpos anti-hla-a2 e usos dos mesmos
SG11202010116PA (en) * 2018-04-13 2020-11-27 Sangamo Therapeutics France Chimeric antigen receptor specific for interleukin-23 receptor
CA3109253A1 (en) 2018-08-10 2020-02-13 Sangamo Therapeutics France New car constructs comprising tnfr2 domains
EP4010377A4 (en) * 2019-08-09 2023-09-06 A2 Biotherapeutics, Inc. CELL SURFACE RECEPTORS THAT RESPOND TO LOSS OF HETEROZYGOSIS
WO2021028359A1 (en) 2019-08-09 2021-02-18 Sangamo Therapeutics France Controlled expression of chimeric antigen receptors in t cells
JP2023506184A (ja) 2019-12-11 2023-02-15 エイ２・バイオセラピューティクス・インコーポレイテッド Ｌｉｌｒｂ１ベースのキメラ抗原受容体
CN111393533B (zh) * 2020-04-16 2021-05-11 成都仕康美生物科技有限公司 靶向HLA-A的嵌合抗原受体、编码基因、CAR-Tregs细胞及其制备方法、用途
CA3188862A1 (en) 2020-08-20 2022-02-24 Carl Alexander Kamb Compositions and methods for treating mesothelin positive cancers
AU2021328478A1 (en) 2020-08-20 2023-04-20 A2 Biotherapeutics, Inc. Compositions and methods for treating egfr positive cancers
CN116724052A (zh) 2020-08-20 2023-09-08 A2生物治疗股份有限公司 用于治疗ceacam阳性癌症的组合物和方法
WO2023076912A2 (en) * 2021-10-26 2023-05-04 ImmPACT Bio USA Inc. Cd4+ and/or cd8+ cell populations comprising icars for use in treatment therapies
WO2023156587A1 (en) * 2022-02-18 2023-08-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of tcr-deficient car-tregs in combination with anti-tcr complex monoclonal antibodies for inducing durable tolerance
WO2023172991A2 (en) * 2022-03-09 2023-09-14 Immpact Bio Usa, Inc. Bicistronic inhibitory chimeric antigen receptor (icar)/activating chimeric antigen receptor (acar) constructs for use in cancer therapies

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB0919751D0 (en) * 2009-11-11 2009-12-30 King S College Hospital Nhs Fo Conjugate molecule
BR122021026173B1 (pt) * 2010-12-09 2023-12-05 The Trustees Of The University Of Pennsylvania Composição farmacêutica
JP2015180607A (ja) * 2012-08-01 2015-10-15 国立大学法人 東京大学 移植片対宿主病などの造血幹細胞移植に伴う疾患を治療することのできる抗体およびその機能断片並びにこれらを含んでなる医薬組成物

Also Published As

Publication number Publication date
RU2020112261A (ru) 2021-10-20
BR112020005361A2 (pt) 2020-09-24
CN111448215B (zh) 2024-01-16
WO2019056099A1 (en) 2019-03-28
EP3684821A1 (en) 2020-07-29
EP3684821A4 (en) 2021-06-16
JP7281774B2 (ja) 2023-05-26
CN111448215A (zh) 2020-07-24
IL273402A (en) 2020-05-31
RU2020112261A3 (es) 2022-03-02
JP2020537537A (ja) 2020-12-24
CA3076261A1 (en) 2019-03-28
US20200283529A1 (en) 2020-09-10
SG11202002520UA (en) 2020-04-29
KR20200067845A (ko) 2020-06-12
JP2023100800A (ja) 2023-07-19
AU2018338418A1 (en) 2020-04-09

Similar Documents

Publication Publication Date Title
MX2020003046A (es) Anticuerpos anti-hla-a2 y metodos para utilizar los mismos.
PH12017500268A1 (en) Antibodies and chimeric antigen receptors specific for cd19
PH12018500295A1 (en) Chimeric antigen receptors based on single-domain antibodies and methods of use thereof
MX2019001184A (es) Anticuerpos anti-idiotípicos y métodos relacionados.
EA201992469A1 (ru) Антигенспецифические иммунные эффекторные клетки
AU2014236098A8 (en) Treatment of cancer using humanized anti-CD19 chimeric antigen receptor
MX2019000643A (es) Receptores de antigenos quimericos y metodos de uso.
MX2022011659A (es) Proteinas de union a antigeno que se unen a pd-l1.
MX2022000132A (es) Inmunoreceptores especificos de claudina-18.2 y epitopos de celulas t.
SA517381703B1 (ar) C10orf54 - أجسام مضادة لـ واستخداماتها
MY190711A (en) Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor
MY194328A (en) Bispecific anti-human a-beta/human transferrin receptor antibodies and methods of use
MX2020006689A (es) Composiciones de vcar y metodos de uso.
MX2021006968A (es) Antígeno quimérico y receptores de las células t, y métodos de uso.
WO2015142675A8 (en) Treatment of cancer using chimeric antigen receptor
MX2017001008A (es) Tratamiento de cancer utilizando un receptor quimerico de antigeno cd33.
MY176294A (en) Antibodies comprising chimeric constant domains
MX2016012713A (es) Inmunoreceptores especificos de claudina-6 y epitopos de celulas t.
IN2014MN01879A (es)
MX343659B (es) Proteínas de unión receptoras fc.
MX2019015352A (es) Linfocitos t con receptor de antigeno quimerico (car) para receptor 1 huerfano tipo receptor de tirosina cinasa (ror 1).
NZ629553A (en) Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
EP3835320A4 (en) BINDING OF CHEMERA ANTIGEN RECEPTOR TO HLA-DR, AND CAR-T CELL
AU2018338423A1 (en) Novel anti-HLA-A2 antibodies and uses thereof
PH12019501605A1 (en) Glucagon receptor binding proteins and methods of use thereof